Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard vs Prolonged Neoadjuvant Chemotherapy for Pancreatic Cancer
NCT06714604Phase 3Recruiting
- Sponsor
- Sahlgrenska University Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2032
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of fluorouracil, folinic acid, irinotecan, oxaliplatin, gemcitabine in pancreatic cancer (PC), sponsored by Sahlgrenska University Hospital. Started Oct 2023; status: recruiting.
02
Drugs
fluorouracilfolinic acidirinotecanoxaliplatingemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06714604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06714604.